Gimoti denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gimoti are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Gimoti as Experimental — and Why You Can Appeal

Blue Cross Blue Shield's experimental or investigational denial for Gimoti (metoclopramide nasal spray) is typically an error in plan policy classification. Gimoti is an FDA-approved drug for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. If BCBS has classified it as experimental, the most likely explanation is that the plan's drug database or coverage policy has not been updated to reflect the FDA approval, or that a legacy experimental classification was applied without review of current regulatory status.

## Why This Denial Is Appealable

A drug with full FDA approval for the precise indication being treated cannot be legitimately classified as experimental under most plan definitions. The appeal argument is straightforward: present the FDA approval record and the plan's own experimental-coverage policy definition, and demonstrate that Gimoti satisfies every criterion for non-experimental status. Under ERISA §503, a plan must provide a full and fair review, which requires that adverse determinations be based on accurate factual and regulatory information.

## Federal Appeal Framework

• Internal appeal (Level 1): File under ACA §2719 / ERISA §503 within the deadline on your denial letter. Experimental denials based on incorrect FDA-status classification are among the most routinely reversed at Level 1.
• External review: If the internal appeal is denied, request IRO review under ACA §2719. The window is typically 4 months from the final adverse benefit determination — verify the exact date on your denial notice.
• Expedited option: If delay would seriously jeopardize health, request expedited review for a 72-hour decision.

## Documentation to Gather

1. FDA approval documentation: Print the official FDA drug approval record for Gimoti from FDA.gov, including the indication and approval date. 2. FDA prescribing label: The full FDA-approved prescribing information, listing the approved adult diabetic gastroparesis indication. 3. Diagnosis confirmation: Clinical records confirming the patient's diagnosis of diabetic gastroparesis and that the prescribing indication matches the FDA-approved use. 4. Professional society references: Citations from the applicable gastroenterology guideline organization regarding the management of gastroparesis, if available, showing that pharmacologic treatment with prokinetics is guideline-consistent. 5. Prescriber medical-necessity letter: A letter from the prescribing physician confirming FDA-approved indication match, that Gimoti is not experimental, and the clinical rationale for its use in this patient.

## Criteria-Mapping Structure

Request BCBS's written experimental/investigational policy. Most plans define experimental coverage using criteria such as FDA approval status, published peer-reviewed clinical evidence, and endorsement by a recognized professional medical organization. Map each criterion:

| Experimental Criterion | Rebuttal Evidence | |---|---| | FDA approval for the treated indication | [FDA.gov approval page — URL, approval date, indication statement] | | Published peer-reviewed clinical evidence | [Prescriber references to published gastroparesis literature] | | Professional society endorsement | [Relevant gastroenterology guideline organization recommendation, if available] |

Open your appeal letter with a direct, factual statement: Gimoti holds full FDA approval for the indication for which it was prescribed. Attach the FDA documentation as the first exhibit. If the plan's experimental-coverage policy requires only FDA approval to clear the experimental threshold, the rebuttal is short and strong.